氨溴索联合孟鲁司特钠治疗难治性哮喘的临床效果

Clinical Effect of Ambroxol Combined with Montelukast Sodium in Treatment of Refractory Asthma

目的:探讨氨溴索联合孟鲁司特钠治疗难治性哮喘的临床效果。方法:选取2019年5月—2022年5月新疆维吾尔自治区人民医院呼吸与危重症医学科收治的难治性哮喘患者74例作为研究对象,采用随机数字表法分为对照组与观察组,各37例。两组均行常规治疗,对照组在常规治疗基础上应用氨溴索治疗,观察组在对照组基础上应用孟鲁司特钠治疗。比较两组治疗效果。结果:观察组治疗总有效率高于对照组,差异有统计学意义(P=0.017)。治疗后,观察组用力肺活量(FVC)、第1秒用力呼气容积(FEV1)、FEV1/FVC高于对照组,差异有统计学意义(P<0.05)。观察组咳嗽、喘息、胸闷、气急缓解时间短于对照组,差异有统计学意义(P<0.05)。治疗后,观察组日间、夜间症状评分低于对照组,差异有统计学意义(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论:氨溴索联合孟鲁司特钠治疗难治性哮喘的效果显著,可改善患者临床症状,提升肺功能,且不会增加不良反应。

Objective:To explore the clinical effect of ambroxol combined with montelukast sodium in treatment of refractory asthma.Methods:A total of 74 patients with refractory asthma treated in the Department of Respiratory and Critical Care Medicine,People's Hospital of Xinjiang Uygur Autonomous Region from May 2019 to May 2022 were selected as the study subjects.They were divided into control group and observation group according to random number table method,with 37 cases in each group.Both groups received conventional treatment,the control group was treated with ambroxol on the basis of conventional treatment,and the observation group was treated with montelukast sodium on the basis of control group.The treatment effects in the two groups were compared.Results:The total effective rate of treatment in the observation group was higher than that in the control group,and the difference was statistically significant(P=0.017).After treatment,the forced vital capacity(FVC),forced expiratory volume in 1 second(FEV1)and FEV1/FVC in the observation group were higher than those in the control group,and the difference was statistically significant(P<0.05).The relief time of cough,wheezing,chest tightness and shortness of breath in the observation group were shorter than those in the control group,and the difference was statistically significant(P<0.05).After treatment,the daytime and nighttime symptom scores in the observation group were lower than those in the control group,and the difference was statistically significant(P<0.05).There was no statistically significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion:The combination of ambroxol and montelukast sodium in the treatment of refractory asthma has significant effects,which can ameliorate clinical symptoms,improve lung function,and will not increase adverse reactions.